Fri, Apr 25, 2014, 12:15 AM EDT - U.S. Markets open in 9 hrs 15 mins

Recent

% | $
Quotes you view appear here for quick access.

Ligand Pharmaceuticals Incorporated Message Board

  • long_vrts2 long_vrts2 Feb 14, 2013 2:05 AM Flag

    cc notes

    A few highlights:

    1. Melphalan pivotal PIII trial going well, will be completed this year. Could be on market in 2014 or early 2015. LGND has received interest from potential partners, will make a decision on whether to go alone with distribution or partner.

    2. Alzheimer's drug licensed to MRK generating a lot of excitement. Going into PII trial with option of extension into PIII. By biomarker assay, the efficacy of the drug looks robust. MRK highlighted this Alz drug in their recent cc.

    3. Higgins affirmed that Promacta is a billion+ drug. Trials in cancer indications going well. GSK has a top team working on expanding indications and global reach for Pro, and the revenue growth has been very solid with a 70% year-over-year growth.

    4. There are 6 partnered drugs that could receive FDA approval and start marketing in the next 3 years.

    Increasing arsenal of approved and partnered drugs, increasing royalties and revenues- sit back and enjoy the ride!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
LGND
68.724-0.456(-0.66%)Apr 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.